ArticlemBio2020
Humans Surviving Cholera Develop Antibodies against Vibrio cholerae O-Specific Polysaccharide That Inhibit Pathogen Motility.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Long-Term Kinetics of Serological Antibodies againstInternational journal of environmental research and public health · 2022Pooled it
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.Frontiers in pediatrics · 2026Article
- Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens.Nature communications · 2025Article
- Human antibody targetingmBio · 2025Article
- Dynamics of IgM and IgA Antibody Response Profile AgainstInternational journal of molecular sciences · 2025Article
- Vaccination of Rabbits with a Cholera Conjugate Vaccine Comprising O-Specific Polysaccharide and a Recombinant Fragment of Tetanus Toxin Heavy Chain Induces Protective Immune Responses against Vibrio cholerae O1.The American journal of tropical medicine and hygiene · 2023Article
- Review
- Metagenomic Analysis of Microbial Contamination in the U.S. Portion of the Tijuana River Watershed.International journal of environmental research and public health · 2022Article
- Virus-like Particle Display ofACS infectious diseases · 2022Article
- Use of a MAIT-Activating Ligand, 5-OP-RU, as a Mucosal Adjuvant in a Murine Model ofPathogens & immunity · 2022Article
- Correlates of Protection for Cholera.The Journal of infectious diseases · 2021Article
- Article
- Interactions between the Prophage 919TP and ItsViruses · 2021Article
- Article
- Systemic, Mucosal, and Memory Immune Responses following Cholera.Tropical medicine and infectious disease · 2021Review
- Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine.Infection and immunity · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 2 countries.
Richelle C CharlesDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8881-1849
Meagan KellyDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jenny M TamDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Aklima AkterDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Motaher HossainDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kamrul IslamDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rajib BiswasDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Mohammad KamruzzamanDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Fahima ChowdhuryInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Ashraful I KhanInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Daniel T LeungDivision of Infectious Diseases, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID 0000-0001-8401-0801
Ana WeilDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Regina C LaRocqueDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Taufiqur Rahman BhuiyanInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Atiqur RahmanInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Leslie M Mayo-SmithDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rowen SeykoraDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jatin M VyasDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-9985-9565
Christina S FahertyDepartment of Pediatrics, MassGeneral Hospital for Children, Boston, Massachusetts, USA.ORCID 0000-0002-3200-161X
Kourtney P NickersonDepartment of Pediatrics, MassGeneral Hospital for Children, Boston, Massachusetts, USA.
Samantha GiffenDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Alaina S RitterDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Matthew K WaldorDepartment of Microbiology, Harvard Medical School, Boston, Massachusetts, USA.
Peng XuNIDDK, LBC, National Institutes of Health, Bethesda, Maryland, USA.
Pavol KováčNIDDK, LBC, National Institutes of Health, Bethesda, Maryland, USA.
Stephen B CalderwoodDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Robert C KauffmanDivision of Infectious Disease, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Jens WrammertDivision of Infectious Disease, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Firdausi Qadri *International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Jason B Harris *Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Edward T Ryan *Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA etryan@mgh.harvard.edu.
International Centre for Diarrhoeal Disease Research · BDHarvard University · USMassachusetts General Hospital · USEmory University · USNational Institutes of Health · USBrigham and Women's Hospital · USUniversity of Utah · US
Funding
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1MImmune Responses to Vibrio cholerae infection and vaccination in HaitiR01AI099243 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B, IVERS, LOUISE C. · 2012 to 2022
$7.9MProtecutive immunity to human cholera in BangladeshU01AI058935 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CALDERWOOD, STEPHEN B., RYAN, EDWARD T. · 2003 to 2014
$7.8MVibrio cholerae intestinal colonization and vaccine developmentR01AI042347 · NIAID · TUFTS UNIVERSITY BOSTON · PI WALDOR, MATTHEW K · 1998 to 2025
$7.3MTraining program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4MO-Specific Polysaccharide Responses and CholeraR37AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Edward T. Ryan · 2020 to 2026
$5.1MAntibody mediated protective immunity against choleraR01AI137164 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHARLES, RICHELLE C, HARRIS, JASON B · 2018 to 2022
$3.9MInnate and early B cell responses to V. choleraeR01AI103055 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B · 2014 to 2018
$3.9MO-Specific Polysaccharide Responses and CholeraR01AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2014 to 2018
$3.7MEstimating Cholera Burden with Cross-sectional Immunologic DataR01AI135115 · NIAID · UNIVERSITY OF UTAH · PI LEUNG, DANIEL TED · 2018 to 2022
$3.4MHuman B cell responses to a live attenuated cholera vaccineR01AI137127 · NIAID · EMORY UNIVERSITY · PI WRAMMERT, JENS PETER · 2018 to 2022
$1.9MMucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccinationR01AI130378 · NIAID · UNIVERSITY OF UTAH · PI LEUNG, DANIEL TED · 2017 to 2021
$1.8MFIC NIH HHS D43 TW005572FIC NIH HHS K43 TW010362Howard Hughes Medical InstituteNIAID NIH HHS K08 AI123494NIAID NIH HHS K22 AI104755NIAID NIH HHS R01 AI042347NIAID NIH HHS R01 AI099243NIAID NIH HHS R01 AI103055NIAID NIH HHS R01 AI106878NIAID NIH HHS R01 AI130378NIAID NIH HHS R01 AI135115NIAID NIH HHS R01 AI137127NIAID NIH HHS R01 AI137164NIAID NIH HHS R37 AI106878NIAID NIH HHS T32 AI007061NIAID NIH HHS U01 AI058935
Abstract
The mechanism of protection against cholera afforded by previous illness or vaccination is currently unknown. We have recently shown that antibodies targeting O-specific polysaccharide (OSP) of
Indexed as
AgglutinationAnimalsAnimals, SucklingAntibodies, BacterialAntibodies, MonoclonalBangladeshCholeraHumansMiceO AntigensVibrio choleraeAntibodies, BacterialAntibodies, MonoclonalO AntigenscholerahumanmotilitypathogenesisVibrio cholerae
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.